Chasing Boehringer, Anaptys hits goal in pivotal rare skin disease trial, plans out-licensing deal

AnaptysBio has set the stage for negotiations over its rare skin disease drug candidate, delivering phase 3 data that suggest the asset can challenge Boehringer Ingelheim in generalized pustular psoriasis (GPP).